Maas Andrew
Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium.
Chin J Traumatol. 2016;19(1):3-6. doi: 10.1016/j.cjtee.2016.01.001.
Traumatic brain injury (TBI) represents a huge global medical and public health problem across all ages and in all populations. In this review, we discussed the changing concepts and approaches. Globally, the incidence is increasing and in high income countries epidemiologic patterns are changing with consequences for prevention campaigns. TBI should not be viewed as an event, but as a progressive and chronic disease with lifetime consequences. In the clinical field, precision approaches to treatment are being developed, which require more accurate disease phenotyping. Recent advances in genomics, neuroimaging and biomarker development offer great opportunities to develop improved phenotyping and better disease characterization. In clinical research, randomized controlled clinical trials are being complemented by large data collections in broad TBI populations in comparative effectiveness designs. Global collaborations are being developed among funding agencies, research organizations and researchers. Only by combining efforts and collaboration will we be able to advance the field by providing long-needed evidence to support practice recommendations and to improve treatment.
创伤性脑损伤(TBI)是一个影响所有年龄和人群的全球性重大医学和公共卫生问题。在本综述中,我们讨论了不断变化的概念和方法。在全球范围内,其发病率正在上升,在高收入国家,流行病学模式正在发生变化,这对预防运动产生了影响。TBI不应被视为一个单一事件,而应被视为一种具有终身影响的进行性慢性疾病。在临床领域,正在开发精准治疗方法,这需要更准确的疾病表型分析。基因组学、神经影像学和生物标志物开发方面的最新进展为改进表型分析和更好地描述疾病特征提供了巨大机遇。在临床研究中,随机对照临床试验正通过比较有效性设计在广泛的TBI人群中进行大数据收集来加以补充。资助机构、研究组织和研究人员之间正在开展全球合作。只有通过共同努力与合作,我们才能通过提供长期以来所需的证据来支持实践建议并改善治疗,从而推动该领域的发展。